Company Overview and News

10
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

7h zacks
Making its debut on 02/23/2012, smart beta exchange traded fund iShares Emerging Markets Dividend ETF (DVYE - Free Report) provides investors broad exposure to the Broad Emerging Market ETFs category of the market.
SSW KDP IEMG SSWN DVYE SSW.PRC SSW.PRH SSW.PRG SSW.PRE SSW.PRD VWO SSWA

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-07-02 zacks
The First Trust BICK Index Fund (BICK - Free Report) made its debut on 04/12/2010, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

5
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-06-27 zacks
The SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) made its debut on 02/23/2011, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
5347 EDIV TNABY IEMG UMC PETFF TNABF ICHR VWO

0
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-06-25 zacks
Making its debut on 02/23/2012, smart beta exchange traded fund iShares Emerging Markets Dividend ETF (DVYE - Free Report) provides investors broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
DVYE SSW IEMG SSW.PRC SSW.PRH SSW.PRG SSW.PRE SSWN SSW.PRD VWO SSWA

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-06-08 zacks
A smart beta exchange traded fund, the First Trust BICK Index Fund (BICK - Free Report) debuted on 04/12/2010, and offers broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-06-07 zacks
The First Trust BICK Index Fund (BICK - Free Report) made its debut on 04/12/2010, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

32
How To Choose The Best China ETF Allocation, After Vanguard's First All-China ETF

2018-05-18 seekingalpha
This month, Vanguard launched its first "total China"-focused ETF in Hong Kong, covering A-shares, H-shares, P, N, B, S and Red Chips for 40bps.
HKXCY MCHI DSUM EWH IEMG 2846 EWT BLK 2800 HAHA VWO EEM

0
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-05-10 zacks
The iShares Emerging Markets Dividend ETF (DVYE - Free Report) made its debut on 02/23/2012, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
DVYE SSW IEMG SSW.PRC SSW.PRH SSW.PRG SSW.PRE SSWN SSW.PRD VWO SSWA

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-05-03 zacks
Launched on 04/12/2010, the First Trust BICK Index Fund (BICK - Free Report) is a smart beta exchange traded fund offering broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

28
Is PowerShares DWA Emerging Markets Momentum Portfolio (PIE) a Hot ETF Right Now?

2018-05-02 zacks
Making its debut on 12/28/2007, smart beta exchange traded fund PowerShares DWA Emerging Markets Momentum Portfolio (PIE - Free Report) provides investors broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
WFC WFCNP WFC.WS IEMG WFC.PRL WFC.PRJ 5168 WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW VWO WFC.PRV MGZZF HRGHY

21
ETF Asset Report for April 2018: Bonds Top

2018-04-30 zacks
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.
AGG IVV IEMG DIA SPY IVV EFA FLOT SHY IEFA

3
Is iShares Edge MSCI Multifactor Emerging Markets ETF (EMGF) a Hot ETF Right Now?

2018-04-27 zacks
Designed to provide broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market, the iShares Edge MSCI Multifactor Emerging Markets ETF (EMGF - Free Report) is a smart beta exchange traded fund launched on 12/08/2015.
EMGF IEMG 0700 INDA VWO

109
U.S. Weekly FundFlows Insight Report: Fund Flows Remain Positive For The Week In Spite Of Market Declines And Rising Yields

2018-04-27 seekingalpha
For the second week in three, investors were net purchasers of fund assets (including those of conventional funds and ETFs), injecting a little more than $8.0 billion. In spite of market declines and rising yields, fund investors were net purchasers of equity funds (+$3.5 billion), money market funds (+$3.3 billion), taxable bond funds (+$0.9 billion), and municipal bond funds (+$229 million) for the fund flows week ended April 25, 2018.
IVV QQQ CAT IEMG VZ IVV UTX BA IWM IEFA

37
Q1 ETF Inflows Dive at BlackRock: Tough Road Ahead?

2018-04-13 zacks
Unlike preceding quarters,net asset inflows to BlackRock Inc.’s (BLK - Free Report) ETF business dropped 46% in the first quarter to $34.6 billion from the year-ago quarter. However, despite a decline in inflows, BlackRock’s first-quarter 2018 adjusted earnings came in at $6.70 per share, which breezed past the Zacks Consensus Estimate of $6.42.
GD BLK SIG IWD IEMG EFA IEFA EEM SIG

13
Is IEMG A Better Play For International Markets Exposure Than IXUS?

2018-04-08 seekingalpha
The iShares Core MSCI Emerging Markets ETF (IEMG) is a top-shelf choice for investors looking to gain exposure to emerging markets.
NPSNY IXUS IEMG BC94 SMSN NPSN SMSD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 46434G103